| Parkinson Disease

Neupro vs Xadago

Side-by-side clinical, coverage, and cost comparison for parkinson disease.

Deep comparison between: Neupro vs Xadago with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsXadago has a higher rate of injection site reactions vs Neupro based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Xadago but not Neupro, including UnitedHealthcare

Category

Neupro

Xadago

At A Glance

RouteTransdermal patch

FrequencyDaily

ClassDopamine agonist

RouteOral

FrequencyDaily

ClassMAO-B inhibitor

Indications

Parkinson Disease
Restless Legs Syndrome

Parkinson Disease

Dosing

Parkinson Disease Early-stage: start 2 mg/24 hours, increase by 2 mg/24 hours weekly, max 6 mg/24 hours; advanced-stage: start 4 mg/24 hours, increase by 2 mg/24 hours weekly, max 8 mg/24 hours; applied transdermally once daily.

Restless Legs Syndrome Start 1 mg/24 hours, increase by 1 mg/24 hours weekly as needed, max 3 mg/24 hours; applied transdermally once daily.

Parkinson Disease Start with 50 mg orally once daily; after two weeks, may increase to 100 mg once daily based on individual need and tolerability; maximum 50 mg once daily in moderate hepatic impairment (Child-Pugh B); contraindicated in severe hepatic impairment (Child-Pugh C).

Contraindications

Hypersensitivity to rotigotine or any component of the transdermal system

Concomitant use of other MAOIs or potent monoamine oxidase inhibitors, including linezolid
Concomitant use of opioid drugs (meperidine and its derivatives, methadone, propoxyphene, or tramadol), SNRIs, tricyclic/tetracyclic/triazolopyridine antidepressants, cyclobenzaprine, methylphenidate, amphetamine and their derivatives, or St John's wort
Concomitant use of dextromethorphan
History of hypersensitivity to safinamide
Severe hepatic impairment (Child-Pugh C: 10-15)

Drug Interactions

668View drug interactions

726View drug interactions

Adverse Reactions

Most common (>=5% above placebo) Application site reactions, nausea, somnolence, dizziness, vomiting, disturbances in initiating and maintaining sleep, peripheral edema, dyskinesia, headache, hyperhidrosis, anorexia, visual disturbance

Serious Sulfite sensitivity, falling asleep during activities of daily living, hallucinations/psychosis, symptomatic hypotension, syncope, impulse control/compulsive behaviors, elevation of blood pressure and heart rate, weight gain and fluid retention, dyskinesia, augmentation and rebound in RLS, hyperpyrexia and confusion, withdrawal symptoms, fibrotic complications

Postmarketing Withdrawal symptoms, dropped head syndrome, rhabdomyolysis

Most common (>=2%) Dyskinesia, fall, nausea, insomnia, orthostatic hypotension, anxiety, cough, dyspepsia

Serious Hypertension, serotonin syndrome, falling asleep during activities of daily living, dyskinesia, hallucinations/psychotic behavior, impulse control/compulsive behaviors, withdrawal-emergent hyperpyrexia and confusion, retinal pathology

Postmarketing Hypersensitivity (swelling of tongue and gingiva, dyspnea, skin rash), headache

Pharmacology

Rotigotine is a non-ergoline dopamine agonist thought to exert its therapeutic effects by stimulating dopamine receptors within the caudate-putamen in Parkinson's disease and dopamine receptors in Restless Legs Syndrome.

MAO-B inhibitor; safinamide selectively inhibits MAO-B with more than 1000-fold selectivity over MAO-A, blocking catabolism of dopamine and thereby increasing dopamine levels and dopaminergic activity in the brain.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Neupro